Formulation and Evaluation of Sustained Release Matrix Tablet of Itopride

Govind Reddy G, Ashok Kumar*, Girisha G R, Suresh V. Kulkarni
Department of Pharmaceutics, Sree Siddaganga college of pharmacy, B. H. Road, Tumkur-572102 Karnataka, India.

ABSTRACT
The objective of this research work was to carry out design and evaluation of sustained release matrix tablets of Itopride by use of natural and synthetic polymers. Matrix tablets were prepared by wet granulation technique by using natural polymers like Carbopol 934, Tamarind poly saccharide, Locust bean gum, Ethyl cellulose, HPMC K 100 as matrix forming agent and excipients such as Lactose, Starch 1500, Magnesium stearate, MCC and talc were used. The dissolution medium consisted of 900 ml of 0.1 N HCl for first 2 hours and then 7.4 phosphate buffer for remaining 10 hours. The release of Itopride from matrix containing lactose, micro crystalline cellulose and starch 1500 as diluents. The drug release rate was found in order of lactose> micro crystalline cellulose>starch 1500. The formulation was optimized on the basis of acceptable tablet properties and in-vitro drug release. The release data were fit into different kinetic models (zero-order, first-order, Higuchi’s equation and Korsmeyer-Peppas equation). Optimized formulation was tested for their compatibility with Itopride by FT-IR studies, which revealed that there is no chemical interaction occurred with polymer and other excipients. The drug release profile of the best formulation was well controlled and uniform throughout the dissolution studies.

Keywords: Matrix tablets, Itopride, Carbopol 934, HPMC K 100, Ethyl cellulose.

*Corresponding Author Email: ashokkumarscp@gmail.com
Received 10 July 2021, Accepted 9 August 2021

Please cite this article as: Kumar A et al., Formulation and Evaluation of Sustained Release Matrix Tablet of Itopride. American Journal of PharmTech Research 2021.
INTRODUCTION

Oral route is the most preferred route for administration of drugs. Tablets are the most popular oral formulations available in the market and preferred by the patients and physicians alike. In long-term therapy for the treatment of chronic disease conditions, conventional formulations are required to be administered in multiple doses, and therefore have several disadvantages.\[1\] Sustained release tablet formulations are much desirable and preferred for such therapy because they offer better patient compliance, maintain uniform drug levels, reduce dose and side effects, and increase safety margin for high-potency drugs.\[2\] Oral drug delivery continues to rise in popularity as formulation scientists look for ways to control drug release and improve patient convenience. However, developing oral sustained release tablets for water soluble drugs with constant release rate has always been a challenge to the pharmaceutical technologist. Most of these water-soluble drugs if not formulated properly, may readily release the drug at a faster rate and produce a toxic concentration of drug on oral administration.\[3\] Hence, it is a challenging task to formulate a suitable table dosage form for prolonged delivery of highly water-soluble drugs. The most commonly used method of modulating the drug release is to include it in a matrix system.\[4\]

Diffusion controlled polymeric matrix devices have been widely used as drug delivery systems owing to their flexibility to obtain a desirable drug release profile, cost effectiveness and broad regulatory acceptance.\[5\] Many polymers have been used in the formulation of matrix based sustained release drug delivery systems. Reports were found on the use of hydrophilic polymers like hydroxy propyl methylcellulose (HPMC), sodium carboxy methylcellulose.\[6\] Carbopol’s\[7\] for the preparation of sustained release (SR) formulations of different drugs.

HPMC, a semisynthetic derivative of cellulose, is a swellable hydrophilic polymer. It contains methoxy and hydroxypropyl substituents on its b-o-glucopyranosyl ring backbone, which makes it very resistant to change in pH or ionic content of the dissolution medium.\[8\] Itopride is used in the treatment of gastrointestinal symptoms caused by reduced gastrointestinal motility, like feeling of gastric fullness, upper abdominal pain, anorexia, heartburn, nausea and vomiting, non-ulcer dyspepsia or chronic gastritis. Itopride hydrochloride, a novel prokinetic agent is best candidate for GERD. Central Composite design has been used to optimize the concentration of different component in the formulation of sustained release tablet. In this design, 2 factors were evaluated by using combination of different concentrations of polymer.\[9\]
MATERIALS AND METHOD

The chemicals used in this study were pure drug like Itopride and polymers like HPMC K 100, Carbopol 934, Locust bean gum, Ethyl cellulose and other excipients like Lactose, Starch 1500, Magnesium stearate, MCC and talc (were procured from Yarrow chemicals, mumbai).

Pre-formulation Study:

Pre-formulation studies were conducted to confirm the compatibility of drug with polymers used. These studies were conducted by using FTIR spectrophotometer. In this method, the IR spectra of pure drug, physical mixtures containing drug and polymers (1:1) and tablet triturate were analyzed.

Evaluation of Flow Properties:

Prepared powder blend of the different formulations were evaluated for angle of repose, loose bulk density, tapped bulk density and compressibility index.

Preparation of Itopride sustained release matrix tablets:

The core tablet was manufactured from granules prepared by conventional wet granulation method using starch. A non-aqueous granulation process was adopted to prepare itopride matrix tablets. The detail process was as follows:

Sifting: The drug and all other ingredients were sifted through sieve # 60.

Mixing: The sifted ingredients were mixed thoroughly in a mortar with pestle for 15min

Preparation of Granules: Paste of starch (5% w/v) was added in well mixed powder till the desired wet mass was formed. This wet mass was sifted through sieve # 16.

Drying: The prepared granules were dried at 60°C for 1 hour in hot air oven, and then it was sifted through sieve # 22 and transferred the granules into a polybag.

Lubrication: Magnesium stearate and talc were sifted through sieve #40 and mixed with the prepared granules in a polybag for 5min.

Compression: Finally, tablets were compressed at 600 mg weight on a 10-station mini rotary tabletting machine (Shakti Pharma tech Pvt. Ltd, Ahmedabad) with 12.1 mm flat-shaped punches natural polymer and synthetic polymers, having different concentrations (1:1, 1:2, 1:0.5 and 1:0.25) were developed to evaluate the drug release and to study the effect of polymer concentration on drug release. (Formulation F-1 to F-10).

Table 1: Tablet composition of Itopride sustained release matrix tablets prepared with different release retardant natural matrices (F-1 to F-10):

| Formulation Code | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 |
|------------------|----|----|----|----|----|----|----|----|----|-----|
| Drug             | 150| 150| 150| 150| 150| 150| 150| 150| 150| 150  |
| Tamarind seed polysaccharide | 300| 150| 75 | 37.5| 150| 75 | 37.5| -  | -  | -   |
| Locust bean gum  | -  | -  | -  | -  | -  | -  | -  | -  | 150| 75  | 37.5|
Evaluation:

Hardness test:
The Monsanto hardness tester was used to determine the tablet hardness. The tablet was held between a fixed and moving jaw. Scale was adjusted to zero; load was gradually increased until the tablet fractured. The value of the load at that point gives a measure of hardness of the tablet. Hardness was expressed in Kg/cm$^2$.

Friability test:
Tablet strength was tested by Roche friabilator. Pre-weighed tablets were allowed for 100 revolutions (4 min), taken out and were dedusted. The percentage weight loss was calculated by rewriting the tablets. The % friability was then calculated by,

$$F = \frac{(W_{\text{initial}}) - (W_{\text{final}})}{(W_{\text{initial}})} \times 100$$

Uniformity of weight:
20 tablets from each of the formulation were weighed individually with an analytical weighing balance (Model: AY-200, SHIMADZU Corporation, and JAPAN). The average weights for each brand as well as the percentage deviation from the mean value were calculated.

Drug content uniformity:
Accurately weighed quantity of the powder tablet equivalent to 100mg of the drug was transferred to 100ml volumetric flask. 50ml of buffer solution of pH-7.4 was added. Mix with the aid of ultrasound for 10min, and then the volume was made up to 100ml with the same buffer solution, mixed solution was filtered through the membrane filter disc with an average pore diameter not greater than 0.45µm. 5ml of the filtrate was diluted to 100 ml with same buffer solution and examined under U.V Spectrophotometry at 257nm.

In Vitro Drug Release:

*In-vitro* drug release studies were carried out using USP dissolution apparatus type II (Electro lab, Mumbai, India) at 50 rpm. The dissolution medium consisted of 900 ml of pH 1.2 for first two

| Material          | HPMC K 100 | Carbapol 934 | Ethyl cellulose | Lactose | MCC | Starch | Magnesium stearate | Talc |
|-------------------|------------|--------------|-----------------|---------|-----|--------|-------------------|------|
| Weight (mg)       | 150        | 75           | 37.5            | -       | -   | -      | 150               | 75   |
|                  | 132        | 132          | 282             | 357     | 132 | 132    | 12                | 12   |
|                  | 132        | 132          | 282             | 357     | 132 | 132    | 12                | 12   |
|                  | 12         | 12           | 12              | 12      | 12  | 12     | 12                | 12   |
|                  | 6          | 6            | 6               | 6       | 6   | 6      | 6                 | 6    |
hours and pH 7.4 phosphate buffers for next 10 hours maintained at 37 ± 0.5°C. The drug release at different time intervals was measured using an ultraviolet visible spectrophotometer (Lab India, Mumbai, India) at 257 nm. The study was performed in triplicate.

RESULTS AND DISCUSSION:
The standard graph of Itopride has shown good linearity with $r^2$ value 0.9959 in pH 7.4 buffer solution which suggests that it obeys the “Beer-Lambert’s law”.

FTIR:
Drug polymer interaction was checked by comparing the IR spectra of the formulations with the IR spectra of the pure drug. There was no significant change in the functional groups between the IR spectra of the pure drug and also no additional peaks were seen in the selected formulations. This confirms that no interaction between drug and excipients.

FTIR OF DRUG
Figure 4: FT-IR of itopride + HPMC

Figure 5: FT-IR of Itopride + karaya gum
**Evaluation of Itopride Tablets:**

The Itopride tablet was evaluated for hardness, thickness, friability, weight variation and drug content uniformity. The hardness was in the range of 5.7 to 6.9 kg/cm², which was in accordance with the matrix tablet. The thickness was from 3.56 to 3.90 mm suggested uniformity in thickness for matrix tablet. The friability was less than 1% indicated good handling of the layers. The weight variation results suggested uniformity in weight of layers.
Table 3: Tablet properties of formulations F1 to F10 of Itopride sustained release matrix tablets.

| Formulation Code | Parameters                | Thickness (mm) | Hardness (Kg/cm²) | Friability (%) | Drug content (%) |
|------------------|---------------------------|----------------|------------------|----------------|------------------|
| F-1              |                           | 3.56 ± 0.12    | 5.9 ± 0.11       | 0.15 ± 0.17    | 99.12            |
| F-2              |                           | 3.63 ± 0.17    | 6.0 ± 0.22       | 0.20 ± 0.45    | 100.01           |
| F-3              |                           | 3.71 ± 0.30    | 5.8 ± 0.14       | 0.31 ± 0.28    | 98.99            |
| F-4              |                           | 3.79 ± 0.07    | 6.0 ± 0.07       | 0.22 ± 0.12    | 100.65           |
| F-5              |                           | 3.82 ± 0.12    | 6.0 ± 0.38       | 0.40 ± 0.34    | 99.98            |
| F-6              |                           | 3.89 ± 0.10    | 6.7 ± 0.19       | 0.45 ± 0.28    | 100.12           |
| F-7              |                           | 3.90 ± 1.20    | 6.9 ± 0.24       | 0.32±0.09      | 100.90           |
| F-8              |                           | 3.66 ± 1.75    | 5.7 ± 0.33       | 0.52±0.02      | 98.79            |
| F-9              |                           | 3.70 ± 1.48    | 6.9 ± 0.12       | 0.28±0.01      | 100.52           |
| F-10             |                           | 3.76 ± 1.51    | 6.3 ± 0.45       | 0.41±0.06      | 99.99            |

Weight variation for tablet formulations (F-1 to F-10)

| Sl. No | F-1  | F-2  | F-3  | F-4  | F-5  | F-6  | F-7  | F-8  | F-9  | F-10 |
|--------|------|------|------|------|------|------|------|------|------|------|
| 1      | 601.1| 600.5| 599.6| 600.5| 599.0| 600.3| 600.4| 599.7| 601.9| 600.9|
| 2      | 601.3| 600.6| 599.4| 599.9| 600.5| 601.2| 598.9| 598.2| 599.2| 599.8|
| 3      | 601.5| 600.0| 600.2| 601.2| 601.1| 600.1| 600.7| 599.9| 600.2| 599.8|
| 4      | 600.2| 598.2| 601.3| 602.4| 601.3| 600.9| 600.4| 599.6| 600.3| 600.2|
| 5      | 600.8| 599.7| 602.0| 600.8| 602.0| 599.8| 602.3| 600.2| 602.1| 500.9|
| 6      | 600.5| 601.1| 600.8| 600.9| 600.4| 599.8| 601.7| 600.1| 4599.8| 601.3|
| 7      | 600.7| 600.7| 699.8| 600.7| 599.6| 600.2| 600.2| 599.5| 599.7| 602.0|
| 8      | 601.6| 600.7| 699.6| 600.2| 600.2| 600.8| 600.8| 600.5| 601.2| 600.8|
| 9      | 600.2| 600.2| 600.3| 600.1| 600.2| 600.7| 600.3| 600.2| 600.8| 599.8|
| 10     | 601.6| 600.3| 601.2| 601.2| 599.8| 600.6| 601.4| 599.9| 600.3| 599.6|

Average Weight

| % Maximum Positive dev. | 0.533 | 0.709 | 0.689 | 0.639 | 0.489 | 0.182 | 0.943 | 0.676 | 0.849 | 0.632 |

In vitro Drug Release Studies:

In-vitro drug release studies were carried out using USP XXII dissolution apparatus type II (Electro lab, Mumbai, India) at 50 rpm. The dissolution medium consisted of 900 ml of pH 7.4 phosphate buffer, maintained at 37 ± 0.5°C. The drug release at different time intervals was measured using an UV spectrophotometer (Lab India, Mumbai, India) at 257 nm.

Table: 5: Percentage drug release of formulations (F1 – F9)

| Time (hrs) | F-1     | F-2     | F-3     | F-4     | F-5     | F-6     | F-7     | F-8     | F-9     | F-10    |
|------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 1          | 19.839  | 18.894  | 29.659  | 33.924  | 19.038  | 25.366  | 33.965  | 21.943  | 24.162  | 31.162  |
| 2          | 27.376  | 26.218  | 35.091  | 42.858  | 22.366  | 39.300  | 42.306  | 28.779  | 37.596  | 40.202  |
| 3          | 39.630  | 33.550  | 45.943  | 57.813  | 30.011  | 49.049  | 53.658  | 36.724  | 48.047  | 55.261  |
| 4          | 44.081  | 39.392  | 55.303  | 63.333  | 33.259  | 58.409  | 58.209  | 44.982  | 56.105  | 60.113  |
| 5          | 46.930  | 46.739  | 62.461  | 67.674  | 39.615  | 65.768  | 63.764  | 49.134  | 62.060  | 66.469  |
| 6          | 49.581  | 52.049  | 68.318  | 76.419  | 42.567  | 73.629  | 71.625  | 56.294  | 71.825  | 74.831  |
| 7          | 55.739  | 58.110  | 74.376  | 87.311  | 51.330  | 78.885  | 82.492  | 62.352  | 76.580  | 86.300  |
| 8          | 62.699  | 66.533  | 80.334  | 94.553  | 65.404  | 86.045  | 88.650  | 69.913  | 84.041  | 92.258  |
| 9          | 73.767  | 74.205  | 86.392  | 99.970  | 72.765  | 92.504  | 99.600  | 75.170  | 99.666  | 97.414  |
$In-vitro$ dissolution profile of F1 to F10

Release Kinetics:

Model fitting for formulation F-2

| Time(hrs) | % CDR  | Log of % drug unreleased | Log time | SQRT | Log % CDR |
|-----------|--------|--------------------------|----------|------|-----------|
| 1         | 14.511 | 1.928                    | 0        | 1    | 1.161     |
| 2         | 29.439 | 1.845                    | 0.301    | 1.414| 1.468     |
| 3         | 34.624 | 1.811                    | 0.477    | 1.732| 1.539     |
| 4         | 49.054 | 1.701                    | 0.602    | 2    | 1.690     |
| 5         | 56.294 | 1.634                    | 0.698    | 2.236| 1.750     |
| 6         | 65.361 | 1.531                    | 0.778    | 2.449| 1.815     |
| 7         | 75.072 | 1.386                    | 0.845    | 2.645| 1.875     |
| 8         | 81.778 | 1.246                    | 0.903    | 2.828| 1.912     |
| 9         | 86.121 | 1.123                    | 0.954    | 3    | 1.935     |
| 10        | 90.036 | 0.971                    | 1        | 3.162| 1.954     |
| 11        | 92.339 | 0.884                    | 1.041    | 3.316| 1.965     |
| 12        | 97.938 | 0.167                    | 1.079    | 3.464| 1.990     |
Zero order plots for the formulation F-2 (Time in hours on x-axis and % CDR on y-axis)

First order plot for the formulation F-2 (Time-hours on x-axis and Log of % drug unreleased on y-axis)

Higuchi’s plot for the formulation F-2 (SQRT time on x-axis and % CDR on y-axis)
CONCLUSION:
In this study sustained release matrix tablet of Itopride was prepared by wet granulation technique using natural and synthetic polymers like Carbopol 934, tamarind poly saccharide, karaya gum, locust bean gum, ethyl cellulose, HPMC K 100, were used as retardant. It was found that increase in the concentration in polymeric ratio decreases the drug release. Itopride hydrochloride, a novel prokinetic agent is best candidate for Gastro esophageal reflux disease (GERD). Itopride 50mg is given thrice in a day given. By developing the sustained release formulation of Itopride hydrochloride, the frequency drug administration can be reduced to once a day and one can obtain good therapeutic response. The prepared formulation is usually taken on an empty stomach about an hour before meals and efficient to overcome Gastro esophageal reflux disease (GERD) for 24 hr.

ACKNOWLEDGMENT:
The authors are thankful to me management, Sree Siddaganga college of pharmacy, for providing necessary facilities to carry out this work.

REFERENCES:
1. Chien YW. Novel Drug Delivery System., New York: USA: Marcel Dekker; 1992:139-96
2. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. Delhi: Vallabh Prakashan; 2002: 155-95.
3. Saleh MA, Yellela SR, Srinivas SP, Satyanaryana V. In Vitro and In Vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble Diltiazem hydrochloride. AAPS Pharm SciTech 2005; 6(1) : E14-E21.
4. Salsa T, Veiga F, Pina ME. Oral controlled-release dosage forms. Cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm 1997; 23(1): 929-938.

5. Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled Release Formulation of Tramadol Hydrochloride Using Hydrophilic and Hydrophobic Matrix System. AAPS Pharm SciTech 2003; 4 (3): 1-6.

6. Ranga RK, Padmalatha DK, Buri P. Cellulose Matrices for Zero-Order Release of Soluble Drugs. Drug Dev Ind Pharm 2008; 14(15-17): 2299 - 2320.

7. Rao R, Sindhura G, Saha RN. Design and in Vitro Evaluation of Zidovudine Oral Controlled Release Tablets Prepared Using Hydroxypropyl Methyl cellulose. Chem Pharm Bull 2008; 56(4): 518-524.

8. Rao R, Sindhura G and Saha RN. Design and in Vitro Evaluation of Zidovudine Oral Controlled Release Tablets Prepared Using Hydroxypropyl Methyl cellulose. Chem Pharm Bull 2008 ; 56(4): 518-524.

9. Jagdale SC, Agavekar AJ, Pandya SV. Kuchekar BS, Chabukswar AR. Formulation and Evaluation of Gastroretentive Drug Delivery System of Propranolol Hydrochloride, AAPS Pharm SciTech 2009; 10(3): 1071–1079.